New York, NY (PRWEB) October 24, 2012
Revolutionizing the existing manufacturing of PET, the NCM facility design incorporates full-scale automation, multi-compound processing capability, cGMP compliance, and built-in redundancy.
Using its proprietary automation and innovative technologies, NCM will supply GMP grade PET radioisotopes for development of imaging biomarkers used in diagnosing cancer, brain disorders and heart diseases.
NCM’s NY-based site facilitates the production of specialty radioisotopes that are currently in short supply in the US. "Our ultra-modern facility in New York has allowed us to attract big pharmaceutical companies for the development of companion diagnostics currently not available in the world. “We are pleased that NCM is leading the innovation in this critical area,” said Anwer Rizvi, President of NCM.
“While the world of PET has changed, the PET industry continues to function in a single-compound processing, non-proprietary drug environment. We are creating a revolution and now PET customers can have access to efficient, reliable, and quality radiopharmaceuticals. We have elevated the status of PET drug manufacturing to the level that the Pharma industry has enjoyed for many years," Mr. Rizvi added.
About NCM USA
NCM is a privately held manufacturer of Positron Emission Tomography (PET) radiopharmaceuticals. Its headquarters are located in Manhattan, New York, and its NYC manufacturing location is in the Bronx. Growing demand for PET Imaging for treatment of cancer, brain disorders and heart disease will require additional PET radiopharmaceutical manufacturing capacity in US. NCM is the future of PET Radiopharmaceutical manufacturing. NCM is elevating the status of PET Drug manufacturing to the level that the Pharma industry has enjoyed for many years.
For more information about NCM USA visit our website: http://www.ncm-usa.com or call (212) 719-2322
Peter J Webner RT(N),CNMT
Vice President Business Development